SYRE News and Press, Spyre Therapeutics Inc.

2026-03-11 01:40:14 ET Spyre Therapeutics, Inc. (SYRE) Leerink Global Healthcare Conference 2026 March 9, 2026 8:40 AM EDT... Read the full article on Seeking Alpha For further details see: Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026...

WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory b...

2026-02-23 10:38:15 ET Commodore Capital disclosed a buy of 400,161 shares of Spyre Therapeutics (NASDAQ:SYRE) , an estimated $10.46 million trade based on quarterly average pricing, per a February 17, 2026, SEC filing. According to a February 17, 2026, SEC filing , Commodor...

Spyre Therapeutics Inc. (SYRE) is expected to report $-0.66 for Q4 2025

On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials  Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment continuing ahead of schedule Enrollment on track in Phase...

WALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic disease...

“6 in ’26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to start in ...

2026-01-01 04:36:34 ET ... Read the full article on Seeking Alpha For further details see: Spyre Therapeutics: Validated Targets, Optimized Delivery

2025-11-04 17:26:47 ET More on Spyre Therapeutics Intelligent Development Could Make Spyre Therapeutics Best In Show Spyre Therapeutics prices public offering of 14.8M shares at $18.50 to raise $275M Spyre Therapeutics announces public offering of common stock and pr...

Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing Initiated Phase 2 SKYWAY basket study of SPY072 evaluating ...